Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2008-6-11
pubmed:abstractText
The proper management of prostate cancer is dependent on appropriate risk categorization, based on pretreatment prostate-specific antigen (PSA), clinical stage and Gleason score (GS). The use of radiotherapy in low-risk (T1-T2a, PSA < 10 ng/ml and GS <or= 6) and intermediate-risk (T1/T2, PSA < 20 ng/ml and GS <or= 7) disease is well established, with comparable results to surgery in the era of modern radiation therapy. However, cancer-related outcomes in some radiotherapy patients might still be improved with the use of adjuvant hormonal therapy. There is presently no clear evidence to support its use in low-risk patients and benefits in intermediate-risk patients need to be elucidated in the era of dose-escalated radiation therapy. Hypofractionated radiotherapy using biologically equivalent doses also has the potential to improve the therapeutic index, given the low alpha / beta ratio of prostate cancer, and to reduce overall treatment time, but the most advantageous regimen needs to be determined. In patients with high-risk disease (T3-T4, PSA > 20 ng/ml or GS >or=6 8), radiation with hormones has become the standard treatment. The issues that remain focus on determining the optimal duration of hormones, assessing the use of locoregional dose escalation and determining the possible benefit from adjuvant chemotherapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:issn
0071-9676
pubmed:author
pubmed:issnType
Print
pubmed:volume
41
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
15-25
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Radiotherapy as primary treatment modality.
pubmed:affiliation
Department of Radiation Oncology, University of Toronto, Toronto, Ont., Canada.
pubmed:publicationType
Journal Article, Review